It has been shown that tarloxotinib is converted into its active form tarloxotinib-E (a potent irreversible metabolite) in a hypoxic tumor microenvironment and it is also an NRG1 fusion inhibitor activating HER2/3. The gene discussed is ERBB2; the disease is neoplasm.